Understanding opioid reward

Trends in Neurosciences

Volumn 38, Issue 4, 2015, Pages 217-225

  Fields, Howard L ^a   Margolis, Elyssa B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Addiction; Midbrain; Morphine; Mu opioid receptor; VTA

Indexed keywords

DOPAMINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NEUROTRANSMITTER; OPIATE; NARCOTIC ANALGESIC AGENT; OPIATE RECEPTOR;

ANALYTICAL ERROR; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG EXPOSURE; FOOD DEPRIVATION; NERVE CELL INHIBITION; NONHUMAN; OPIATE ADDICTION; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; REINFORCEMENT; REVIEW; REWARD; VENTRAL TEGMENTUM; WORKING MEMORY; ANIMAL; DRUG EFFECTS; HUMAN;

ANALGESICS, OPIOID; ANIMALS; DOPAMINERGIC NEURONS; HUMANS; RECEPTORS, OPIOID; RECEPTORS, OPIOID, MU; REINFORCEMENT (PSYCHOLOGY); REWARD; VENTRAL TEGMENTAL AREA;

EID: 84926135330     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2015.01.002     Document Type: Review

References (131)

1. Fields H.L. The doctor's dilemma: opiate analgesics and chronic pain. Neuron 2011, 69:591-594.
2. Hall A.J., et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008, 300:2613-2620.
3. Salamone J.D., Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron 2012, 76:470-485.
4. Dalley J.W., et al. Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry. Pharmacol. Biochem. Behav. 2008, 90:250-260.
5. Bromberg-Martin E.S., et al. Dopamine in motivational control: rewarding, aversive, and alerting. Neuron 2010, 68:815-834.
6. Tunbridge E.M., et al. The role of catechol-O-methyltransferase in reward processing and addiction. CNS Neurol. Disord. Drug Targets 2012, 11:306-323.
7. Schultz W. Updating dopamine reward signals. Curr. Opin. Neurobiol. 2013, 23:229-238.
8. Ting-A-Kee R., van der Kooy D. The neurobiology of opiate motivation. Cold Spring Harb. Perspect. Med. 2012, 2:a012096.
9. Le Merrer J., et al. Reward processing by the opioid system in the brain. Physiol. Rev. 2009, 89:1379-1412.
10. Nicola S.M. The nucleus accumbens as part of a basal ganglia action selection circuit. Psychopharmacology 2007, 191:521-550.
11. Hong S. Dopamine system: manager of neural pathways. Front. Hum. Neurosci. 2013, 7:854.
12. McNamara C.G., et al. Dopaminergic neurons promote hippocampal reactivation and spatial memory persistence. Nat. Neurosci. 2014, 17:1658-1660.
13. Kieffer B.L. Opioids: first lessons from knockout mice. Trends Pharmacol. Sci. 1999, 20:19-26.
14. Olmstead M.C., Franklin K.B. The development of a conditioned place preference to morphine: effects of microinjections into various CNS sites. Behav. Neurosci. 1997, 111:1324-1334.
15. Zhang Y., et al. Mu opioid receptor knockdown in the substantia nigra/ventral tegmental area by synthetic small interfering RNA blocks the rewarding and locomotor effects of heroin. Neuroscience 2009, 158:474-483.
16. Britt M.D., Wise R.A. Ventral tegmental site of opiate reward: antagonism by a hydrophilic opiate receptor blocker. Brain Res. 1983, 258:105-108.
17. Zangen A., et al. Rewarding and psychomotor stimulant effects of endomorphin-1: anteroposterior differences within the ventral tegmental area and lack of effect in nucleus accumbens. J. Neurosci. 2002, 22:7225-7233.
18. Bozarth M.A., Wise R.A. Intracranial self-administration of morphine into the ventral tegmental area in rats. Life Sci. 1981, 28:551-555.
19. David V., Cazala P. Differentiation of intracranial morphine self-administration behavior among five brain regions in mice. Pharmacol. Biochem. Behav. 1994, 48:625-633.
20. David V., Cazala P. Anatomical and pharmacological specificity of the rewarding effect elicited by microinjections of morphine into the nucleus accumbens of mice. Psychopharmacology 2000, 150:24-34.
21. Phillips A.G., LePiane F.G. Reinforcing effects of morphine microinjection into the ventral tegmental area. Pharmacol. Biochem. Behav. 1980, 12:965-968.
22. Bozarth M.A., Wise R.A. Anatomically distinct opiate receptor fields mediate reward and physical dependence. Science 1984, 224:516-517.
23. Bals-Kubik R., et al. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J. Pharmacol. Exp. Ther. 1993, 264:489-495.
24. Nader K., van der Kooy D. Deprivation state switches the neurobiological substrates mediating opiate reward in the ventral tegmental area. J. Neurosci. 1997, 17:383-390.
25. Castro D.C., Berridge K.C. Opioid hedonic hotspot in nucleus accumbens shell: mu, delta, and kappa maps for enhancement of sweetness 'liking' and 'wanting'. J. Neurosci. 2014, 34:4239-4250.
26. Fields H.L., et al. Ventral tegmental area neurons in learned appetitive behavior and positive reinforcement. Annu. Rev. Neurosci. 2007, 30:289-316.
27. Ornstein K., et al. Biochemical and radioautographic evidence for dopaminergic afferents of the locus coeruleus originating in the ventral tegmental area. J. Neural Transm. 1987, 70:183-191.
28. Beitz A.J. The organization of afferent projections to the midbrain periaqueductal gray of the rat. Neuroscience 1982, 7:133-159.
29. Beckstead R.M., et al. Efferent connections of the substantia nigra and ventral tegmental area in the rat. Brain Res. 1979, 175:191-217.
30. Fallon J.H. Collateralization of monoamine neurons: mesotelencephalic dopamine projections to caudate, septum, and frontal cortex. J. Neurosci. 1981, 1:1361-1368.
31. Swanson L.W. The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res. Bull. 1982, 9:321-353.
32. Ford C.P., et al. Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J. Neurosci. 2006, 26:2788-2797.
33. Margolis E.B., et al. Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:2938-2942.
34. Margolis E.B., et al. Midbrain dopamine neurons: projection target determines action potential duration and dopamine D(2) receptor inhibition. J. Neurosci. 2008, 28:8908-8913.
35. Lammel S., et al. Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron 2008, 57:760-773.
36. Lammel S., et al. Projection-specific modulation of dopamine neuron synapses by aversive and rewarding stimuli. Neuron 2011, 70:855-862.
37. Carr D.B., Sesack S.R. GABA-containing neurons in the rat ventral tegmental area project to the prefrontal cortex. Synapse 2000, 38:114-123.
38. Yamaguchi T., et al. Mesocorticolimbic glutamatergic pathway. J. Neurosci. 2011, 31:8476-8490.
39. Brown M.T., et al. Ventral tegmental area GABA projections pause accumbal cholinergic interneurons to enhance associative learning. Nature 2012, 492:452-456.
40. Greenwell T.N., et al. Endomorphin-1 and -2 immunoreactive cells in the hypothalamus are labeled by fluoro-gold injections to the ventral tegmental area. J. Comp. Neurol. 2002, 454:320-328.
41. Sesack S.R., Pickel V.M. Dual ultrastructural localization of enkephalin and tyrosine hydroxylase immunoreactivity in the rat ventral tegmental area: multiple substrates for opiate-dopamine interactions. J. Neurosci. 1992, 12:1335-1350.
42. Bausch S.B., et al. Colocalization of mu opioid receptors with GIRK1 potassium channels in the rat brain: an immunocytochemical study. Receptors Channels 1995, 3:221-241.
43. Garzon M., Pickel V.M. Plasmalemmal mu-opioid receptor distribution mainly in nondopaminergic neurons in the rat ventral tegmental area. Synapse 2001, 41:311-328.
44. Spanagel R., et al. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:2046-2050.
45. Devine D.P., et al. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J. Pharmacol. Exp. Ther. 1993, 266:1236-1246.
46. Yoshida M., et al. Facilitatory modulation of mesolimbic dopamine neuronal activity by a mu-opioid agonist and nicotine as examined with in vivo microdialysis. Brain Res. 1993, 624:277-280.
47. Di Chiara G., Imperato A. Preferential stimulation of dopamine release in the nucleus accumbens by opiates, alcohol, and barbiturates: studies with transcerebral dialysis in freely moving rats. Ann. N. Y. Acad. Sci. 1986, 473:367-381.
48. Chefer V.I., et al. Basal and morphine-evoked dopaminergic neurotransmission in the nucleus accumbens of MOR- and DOR-knockout mice. Eur. J. Neurosci. 2003, 18:1915-1922.
49. Gysling K., Wang R.Y. Morphine-induced activation of A10 dopamine neurons in the rat. Brain Res. 1983, 277:119-127.
50. Melis M., et al. Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. Prog. Neuropsychopharmacol. Biol. Psychiatry 2000, 24:993-1006.
51. Jalabert M., et al. Neuronal circuits underlying acute morphine action on dopamine neurons. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:16446-16450.
52. Kiyatkin E.A., Rebec G.V. Impulse activity of ventral tegmental area neurons during heroin self-administration in rats. Neuroscience 2001, 102:565-580.
53. Matthews R.T., German D.C. Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine. Neuroscience 1984, 11:617-625.
54. Johnson S.W., North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 1992, 12:483-488.
55. Kiyatkin E.A., Rebec G.V. Activity of presumed dopamine neurons in the ventral tegmental area during heroin self-administration. Neuroreport 1997, 8:2581-2585.
56. Margolis E.B., et al. The ventral tegmental area revisited: is there an electrophysiological marker for dopaminergic neurons?. J. Physiol. 2006, 577:907-924.
57. Margolis E.B., et al. Identification of rat ventral tegmental area GABAergic neurons. PLoS ONE 2012, 7:e42365.
58. Cohen J.Y., et al. Neuron-type-specific signals for reward and punishment in the ventral tegmental area. Nature 2012, 482:85-88.
59. Hnasko T.S., et al. Morphine reward in dopamine-deficient mice. Nature 2005, 438:854-857.
60. Bechara A., et al. Neurobiology of motivation: double dissociation of two motivational mechanisms mediating opiate reward in drug-naive versus drug-dependent animals. Behav. Neurosci. 1992, 106:798-807.
61. Laviolette S.R., et al. Motivational state determines the functional role of the mesolimbic dopamine system in the mediation of opiate reward processes. Behav. Brain Res. 2002, 129:17-29.
62. Riad-Allen L., van der Kooy D. Social defeat stress switches the neural system mediating benzodiazepine conditioned motivation. Behav. Neurosci. 2013, 127:515-523.
63. Vargas-Perez H., et al. Ventral tegmental area BDNF induces an opiate-dependent-like reward state in naive rats. Science 2009, 324:1732-1734.
64. Bechara A., van der Kooy D. A single brain stem substrate mediates the motivational effects of both opiates and food in nondeprived rats but not in deprived rats. Behav. Neurosci. 1992, 106:351-363.
65. Witten I.B., et al. Recombinase-driver rat lines: tools, techniques, and optogenetic application to dopamine-mediated reinforcement. Neuron 2011, 72:721-733.
66. Kim K.M., et al. Optogenetic mimicry of the transient activation of dopamine neurons by natural reward is sufficient for operant reinforcement. PLoS ONE 2012, 7:e33612.
67. Tsai H.C., et al. Phasic firing in dopaminergic neurons is sufficient for behavioral conditioning. Science 2009, 324:1080-1084.
68. Steinberg E.E., et al. A causal link between prediction errors, dopamine neurons and learning. Nat. Neurosci. 2013, 16:966-973.
69. Li X., et al. Heterogeneous composition of dopamine neurons of the rat A10 region: molecular evidence for diverse signaling properties. Brain Struct. Funct. 2013, 218:1159-1176.
70. Williams J.T., et al. Cellular and synaptic adaptations mediating opioid dependence. Physiol. Rev. 2001, 81:299-343.
71. Kelley A.E., et al. Interactions between D-ala-met-enkephalin, A10 dopaminergic neurones, and spontaneous behaviour in the rat. Behav. Brain Res. 1980, 1:3-24.
72. Nicoll R.A., et al. Enkephalin blocks inhibitory pathways in the vertebrate CNS. Nature 1980, 287:22-25.
73. Lacey M.G., et al. Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta. J. Physiol. 1987, 392:397-416.
74. Johnson S.W., North R.A. Two types of neurone in the rat ventral tegmental area and their synaptic inputs. J. Physiol. 1992, 450:455-468.
75. Chieng B., et al. Distinct cellular properties of identified dopaminergic and GABAergic neurons in the mouse ventral tegmental area. J. Physiol. 2011, 589:3775-3787.
76. Omelchenko N., Sesack S.R. Ultrastructural analysis of local collaterals of rat ventral tegmental area neurons: GABA phenotype and synapses onto dopamine and GABA cells. Synapse 2009, 63:895-906.
77. van Zessen R., et al. Activation of VTA GABA neurons disrupts reward consumption. Neuron 2012, 73:1184-1194.
78. Bocklisch C., et al. Cocaine disinhibits dopamine neurons by potentiation of GABA transmission in the ventral tegmental area. Science 2013, 341:1521-1525.
79. Balcita-Pedicino J.J., et al. The inhibitory influence of the lateral habenula on midbrain dopamine cells: ultrastructural evidence for indirect mediation via the rostromedial mesopontine tegmental nucleus. J. Comp. Neurol. 2011, 519:1143-1164.
80. Matsui A., Williams J.T. Opioid-sensitive GABA inputs from rostromedial tegmental nucleus synapse onto midbrain dopamine neurons. J. Neurosci. 2011, 31:17729-17735.
81. Matsui A., et al. Separate GABA afferents to dopamine neurons mediate acute action of opioids, development of tolerance, and expression of withdrawal. Neuron 2014, 82:1346-1356.
82. Hjelmstad G.O., et al. Opioid modulation of ventral pallidal afferents to ventral tegmental area neurons. J. Neurosci. 2013, 33:6454-6459.
83. Xia Y., et al. Nucleus accumbens medium spiny neurons target non-dopaminergic neurons in the ventral tegmental area. J. Neurosci. 2011, 31:7811-7816.
84. Margolis E.B., et al. Delta-opioid receptor expression in the ventral tegmental area protects against elevated alcohol consumption. J. Neurosci. 2008, 28:12672-12681.
85. Margolis E.B., et al. Both kappa and mu opioid agonists inhibit glutamatergic input to ventral tegmental area neurons. J. Neurophysiol. 2005, 93:3086-3093.
86. Bonci A., Malenka R.C. Properties and plasticity of excitatory synapses on dopaminergic and GABAergic cells in the ventral tegmental area. J. Neurosci. 1999, 19:3723-3730.
87. Harris G.C., et al. Glutamate-associated plasticity in the ventral tegmental area is necessary for conditioning environmental stimuli with morphine. Neuroscience 2004, 129:841-847.
88. Margolis E.B., et al. Direct bidirectional mu-opioid control of midbrain dopamine neurons. J. Neurosci. 2014, 34:14707-14716.
89. Shippenberg T.S., Herz A. Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists. Brain Res. 1987, 436:169-172.
90. Cachope R., et al. Selective activation of cholinergic interneurons enhances accumbal phasic dopamine release: setting the tone for reward processing. Cell Rep. 2012, 2:33-41.
91. Threlfell S., et al. Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron 2012, 75:58-64.
92. Narita M., et al. Implication of dopaminergic projection from the ventral tegmental area to the anterior cingulate cortex in mu-opioid-induced place preference. Addict. Biol. 2010, 15:434-447.
93. Lintas A., et al. Identification of a dopamine receptor-mediated opiate reward memory switch in the basolateral amygdala-nucleus accumbens circuit. J. Neurosci. 2011, 31:11172-11183.
94. Cameron D.L., et al. A subset of ventral tegmental area neurons is inhibited by dopamine, 5-hydroxytryptamine and opioids. Neuroscience 1997, 77:155-166.
95. Margolis E.B., et al. Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons. J. Neurosci. 2003, 23:9981-9986.
96. Brischoux F., et al. Phasic excitation of dopamine neurons in ventral VTA by noxious stimuli. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:4894-4899.
97. Lammel S., et al. Input-specific control of reward and aversion in the ventral tegmental area. Nature 2012, 491:212-217.
98. Ford C.P., et al. Control of extracellular dopamine at dendrite and axon terminals. J. Neurosci. 2010, 30:6975-6983.
99. Dahlstroem A., Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand 1964, 232(Suppl.):231-255.
100. Björklund A., Dunnett S.B. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007, 30:194-202.
101. Sanchez-Catalan M.J., et al. The antero-posterior heterogeneity of the ventral tegmental area. Neuroscience 2014, 282C:198-216.
102. Fallon J.H., Moore R.Y. Catecholamine innervation of the basal forebrain. III. Olfactory bulb, anterior olfactory nuclei, olfactory tubercle and piriform cortex. J. Comp. Neurol. 1978, 180:533-544.
103. Ungerstedt U. Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol. Scand. 1971, 367(Suppl.):1-48.
104. Yetnikoff L., et al. An update on the connections of the ventral mesencephalic dopaminergic complex. Neuroscience 2014, 282C:23-48.
105. Omelchenko N., Sesack S.R. Laterodorsal tegmental projections to identified cell populations in the rat ventral tegmental area. J. Comp. Neurol. 2005, 483:217-235.
106. Carr D.B., Sesack S.R. Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J. Neurosci. 2000, 20:3864-3873.
107. Di Chiara G., et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 2004, 47(Suppl. 1):227-241.
108. Mitchell J.M., et al. Intra-VTA deltorphin, but not DPDPE, induces place preference in ethanol-drinking rats: distinct DOR-1 and DOR-2 mechanisms control ethanol consumption and reward. Alcohol. Clin. Exp. Res. 2014, 38:195-203.
109. Barak S., et al. Glial cell line-derived neurotrophic factor reverses alcohol-induced allostasis of the mesolimbic dopaminergic system: implications for alcohol reward and seeking. J. Neurosci. 2011, 31:9885-9894.
110. Wang J., et al. Nucleus accumbens-derived glial cell line-derived neurotrophic factor is a retrograde enhancer of dopaminergic tone in the mesocorticolimbic system. J. Neurosci. 2010, 30:14502-14512.
111. Hamilton M.E., Freeman A.S. Effects of administration of cholecystokinin into the VTA on DA overflow in nucleus accumbens and amygdala of freely moving rats. Brain Res. 1995, 688:134-142.
112. Laitinen K., et al. Neurotensin and cholecystokinin microinjected into the ventral tegmental area modulate microdialysate concentrations of dopamine and metabolites in the posterior nucleus accumbens. Brain Res. 1990, 523:342-346.
113. Pettit H.O., Mueller K. Infusions of cholecystokinin octapeptide into the ventral tegmental area potentiate amphetamine conditioned place preferences. Psychopharmacology 1989, 99:423-426.
114. Devine D.P., et al. Mesolimbic dopamine neurotransmission is increased by administration of mu-opioid receptor antagonists. Eur. J. Pharmacol. 1993, 243:55-64.
115. Shippenberg T.S., Bals-Kubik R. Involvement of the mesolimbic dopamine system in mediating the aversive effects of opioid antagonists in the rat. Behav. Pharmacol. 1995, 6:99-106.
116. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog. Neurobiol. 1998, 56:613-672.
117. Tzschentke T.M. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict. Biol. 2007, 12:227-462.
118. Stuber G.D., et al. Dopaminergic terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate. J. Neurosci. 2010, 30:8229-8233.
119. Tecuapetla F., et al. Glutamatergic signaling by mesolimbic dopamine neurons in the nucleus accumbens. J. Neurosci. 2010, 30:7105-7110.
120. Gorelova N., et al. The glutamatergic component of the mesocortical pathway emanating from different subregions of the ventral midbrain. Cereb. Cortex 2012, 22:327-336.
121. Root D.H., et al. Single rodent mesohabenular axons release glutamate and GABA. Nat. Neurosci. 2014, 17:1543-1551.
122. Tritsch N.X., et al. Dopaminergic neurons inhibit striatal output through non-canonical release of GABA. Nature 2012, 490:262-266.
123. Stamatakis A.M., et al. A unique population of ventral tegmental area neurons inhibits the lateral habenula to promote reward. Neuron 2013, 80:1039-1053.
124. Schalling M., et al. Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and in humans with schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:8427-8431.
125. Savasta M., et al. The colocalization of cholecystokinin and tyrosine hydroxylase mRNAs in mesencephalic dopaminergic neurons in the rat brain examined by in situ hybridization. Neuroscience 1989, 29:363-369.
126. Seroogy K., et al. Cholecystokinin and tyrosine hydroxylase messenger RNAs in neurons of rat mesencephalon: peptide/monoamine coexistence studies using in situ hybridization combined with immunocytochemistry. Exp. Brain Res. 1989, 74:149-162.
127. Seroogy K., et al. A subpopulation of dopaminergic neurons in rat ventral mesencephalon contains both neurotensin and cholecystokinin. Brain Res. 1988, 455:88-98.
128. Seroogy K.B., Gall C.M. Expression of neurotrophins by midbrain dopaminergic neurons. Exp. Neurol. 1993, 124:119-128.
129. Wang H.L., Morales M. Corticotropin-releasing factor binding protein within the ventral tegmental area is expressed in a subset of dopaminergic neurons. J. Comp. Neurol. 2008, 509:302-318.
130. Grieder T.E., et al. VTA CRF neurons mediate the aversive effects of nicotine withdrawal and promote intake escalation. Nat. Neurosci. 2014, 17:1751-1758.
131. Hamilton M.E., et al. Overflow of dopamine and cholecystokinin in rat nucleus accumbens in response to acute drug administration. Synapse 2000, 38:238-242.